Physician profile
Gina Deblasio
NPI 1710391784
$5,875.19
in general payments reported to CMS, 2019-2025
25 companies · $942 in 2025
The $942 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,097 · 2022: $1,284 · 2023: $1,486 · 2024: $1,065 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.69 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,029.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $620.17 | 2021-2025 | |
| Janssen Biotech, INC. | $594.16 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $505.53 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $403.26 | 2023-2024 | Sotyktu |
| Incyte Corporation | $353.95 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $319.26 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $270.01 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $254.02 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $247.34 | 2024 | Vtama |
| Ucb, INC. | $237.22 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.98 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $211.55 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Journey Medical Corporation | $95.42 | 2022-2025 | |
| Amgen INC. | $89.08 | 2021-2025 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $65.26 | 2022 | |
| Arcutis Biotherapeutics, INC. | $64.20 | 2023-2025 | Zoryve |
| Genzyme Corporation | $53.85 | 2022-2023 | |
| Revance Therapeutics, INC. | $45.70 | 2025 | Daxxify |
| Medimetriks Pharmaceuticals, INC. | $45.39 | 2025 | |
| Vyne Pharmaceuticals INC. | $45.25 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $32.69 | 2025 | Dupixent |
| Misonix INC | $21.79 | 2021 | |
| Almirall LLC | $18.74 | 2021 | |
| Biofrontera INC. | $16.39 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Deblasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.